Clinically, cognitive decline in AD is positively correlated with reduced levels of the neurotransmitter ACh in the brain, underscoring the therapeutic rationale for acetylcholinesterase (AChE) inhibition to preserve synaptic ACh levels and mitigate symptomatology [89,90]. The gene discussed is ACHE; the disease is Mental deterioration.